HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development and characterization of doxorubicin loaded microparticles against experimental visceral leishmaniasis.

Abstract
Visceral leishmaniasis (VL) is the most severe of all the forms of leishmaniasis and usually lethal if untreated. The present work aimed to develop and characterize doxorubicin loaded mannan conjugated microparticles against experimental visceral leishmaniasis for selective and targeted delivery of doxorubicin to the macrophages of liver and spleen for the effective chemotherapy of VL. Macrophage targeting using doxorubicin loaded PLGA-microparticles would certainly improve the chemotherapy with reduced side effects against VL.
AuthorsSheeshpal Sharma, Pankaj Kumar, Anil Jaiswal, Anuradha Dube, Swati Gupta
JournalJournal of biomedical nanotechnology (J Biomed Nanotechnol) Vol. 7 Issue 1 Pg. 135-6 (Feb 2011) ISSN: 1550-7033 [Print] United States
PMID21485839 (Publication Type: Journal Article)
Chemical References
  • Capsules
  • Drug Carriers
  • Doxorubicin
Topics
  • Capsules
  • Cell Survival (drug effects)
  • Doxorubicin (administration & dosage, chemistry)
  • Drug Carriers (chemical synthesis)
  • Leishmania (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: